

Approved



**Lesotho**  
**Country Operational Plan**  
**FY 2018**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		339,451		339,451	0	339,451
USAID		38,315,573	6,400,000	44,715,573	648,328	45,363,901
DOD		481,237		481,237	67,120	548,357
PC		774,501		774,501	34,291	808,792
HHS/CDC	512,500	33,112,843		33,625,343	1,674,011	35,299,354
State/AF		150,000		150,000	0	150,000
<b>Total</b>	<b>512,500</b>	<b>73,173,605</b>	<b>6,400,000</b>	<b>80,086,105</b>	<b>2,423,750</b>	<b>82,509,855</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						Total
	State	DOD	HHS/CDC	PC	State/AF	USAID	
CIRC		153,973	0	0	0	5,381,091	5,535,064
HBHC		19,323	1,171,201	0	60,000	1,988,696	3,239,220
HKID		0	0	126,642	30,000	4,879,135	5,035,777
HLAB		53,973	991,883	0	0	0	1,045,856
HMBL		0	0	0	0	0	0
HMIN		0	0	0	0	0	0
HTXD		0	0	0	0	0	0
HTXS		78,497	13,920,636	0	0	14,558,859	28,557,992
HVAB		0	0	0	0	700,000	700,000
HVCT		7,300	9,969,833	0	0	2,194,368	12,171,501
HVMS	339,451	40,070	1,844,658	621,650		3,371,274	6,217,103
HVOP		3,973	443,078	26,209	0	5,173,413	5,646,673

Approved



HVSI		103,973	914,436	0	0	370,869	<b>1,389,278</b>
HVTB		20,155	2,661,935	0	0	3,730,731	<b>6,412,821</b>
IDUP		0	0	0	0	0	<b>0</b>
MTCT		0	180,181	0	0	370,918	<b>551,099</b>
OHSS		0	311,994	0	0	575,420	<b>887,414</b>
PDCS		0	574,390	0	60,000	296,816	<b>931,206</b>
PDTX		0	641,118	0	0	1,123,983	<b>1,765,101</b>
	<b>339,451</b>	<b>481,237</b>	<b>33,625,343</b>	<b>774,501</b>	<b>150,000</b>	<b>44,715,573</b>	<b>80,086,105</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	3,198,161
HKID	5,008,102
HVTB	6,180,570
PDCS	862,067
<b>Total Technical Area Planned Funding:</b>	<b>15,248,900</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	877,912
HVSI	650,000
OHSS	581,200
<b>Total Technical Area Planned Funding:</b>	<b>2,109,112</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	5,319,914
HMBL	0
HMIN	0
HVAB	700,000
HVCT	12,092,230
HVOP	5,584,858
IDUP	0
MTCT	476,927
<b>Total Technical Area Planned Funding:</b>	<b>24,173,929</b>

Approved



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>
HTXD	0
HTXS	28,319,915
PDTX	1,695,962
<b>Total Technical Area Planned Funding:</b>	<b>30,015,877</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	95 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	47,671
	Number of new ANC and L&D clients	50,060
	By Age (Denominator): 10-14	209
	By Age (Denominator): <15-19	10,590
	By Age (Denominator): 20-24	16,184
	By Number of known positives: 15-19	509
	By Number of known positives: 20-24	1,989
	By Number of new positives: 10-14	1
	By Number of new positives: 15-19	409
	By Number of new positives: 20-24	1,501
	By Number of new positives: 50+	1
	By Number of new negative: 10-14	204
	By Number of new negative: 15-19	9,147
	By Number of new negative: 20-24	11,860
	By Number of new negative: 50+	84
	By Age (Numerator): 10-14	205
	By Age (Numerator): 15-19	10,054
By Age (Numerator): 20-24	15,375	



	By Age (Numerator): 50+	87
	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	10,735
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	7,408
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	3,972
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	962
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	1,949
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	6,993
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	1,277
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	2,599
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	4,016
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	431
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	1,171
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Negative	2,189
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female,	413



	Newly Identified Positive	
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	439
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	305
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	184
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	10,202
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	7,042
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	3,777
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	929
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	26 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	12,227
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	47,671
	New on ART	3,478
	Already on ART at beginning of current pregnancy	8,749





VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	36,719
	By Age: 10-14	14,581
	By Age: 15-19	11,105
	By Age: 20-24	7,328
	By Age: 25-29	3,698
	By Age: 50+	7
	By circumcision technique: Surgical VMMC	36,540
	By circumcision technique: Device-based VMMC	179
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	12,429
	Male 15-19	714
	Male 20-24	722
	Male 50+	932
	Female 15-19	1,112
	Female 20-24	1,152
	Female 50+	1,606
	FSW	513
	MSM	1,043
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	994



	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	587
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	899
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	634
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	861
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	669
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	872
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	675
	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	2,254
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	92,517
	Age/sex: 10-14 Male	961
	Age/sex: 15-19 Male	3,968
	Age/sex: 20-24 Male	14,728
	Age/sex: 50+ Male	951
	Age/sex: 10-14 Female	17,993
	Age/sex: 15-19 Female	17,036
Age/sex: 20-24 Female	7,317	



	Age/sex: 50+ Female	2,608
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	2,608
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	5,218
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	2,608
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	4,348
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	870
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	3,479
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	870
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	6,954
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,599
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that	4,131



	are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,468
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	15,453
	Total number of registered new and relapsed TB cases, during the reporting period.	15,457
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	333
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9,250
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	353



	reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,517
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	340
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9,257
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	340
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5,520
HTS_SELF_DSD	HTS_SELF_N_DSD	197,655
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Directly-Assisted	1,715
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Unassisted	5
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Directly-Assisted	1,173
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Unassisted	41
	HTS_SELF_N_DSD_Age_Sex_HI	13,627



	VSelfTest 15-19, Female, Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	2,384
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	8,242
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	3,177
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	22,553
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Unassisted	10,124
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	13,044
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	3,133
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	10,609
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	5,258
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	12,127
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	3,980
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	10,386



HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	5,004
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	11,348
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	3,795
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	9,728
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	4,273
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	11,080
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	3,052
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	9,421
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	3,917
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	11,365
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	3,038
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Directly-Assisted	4,426
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	102



	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Directly-Assisted	2,765
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	101
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest Unknown Age, Female, Directly-Assisted	29
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest Unknown Age, Female, Unassisted	0
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest Unknown Age, Male, Directly-Assisted	11
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest Unknown Age, Male, Unassisted	0
	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	152,355
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	45,300
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Self	41,586
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Sex Partner	2,897
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	813,148
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	149
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	21
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	120





	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	17
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	224
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	12
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	92
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	319
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	20
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	89
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	367
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	37
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	149
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	8
	Service Delivery Point (Facility) Inpatient: <1, Negative	225
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,004
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	2,488
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	44
	Service Delivery Point (Community) Mobile Testing: 10-14, Male,	2,037



	Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	18
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	8,985
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	93
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	4,903
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	22
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	3,506
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	268
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,215
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	149
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	2,318
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	56
	Service Delivery Point (Community)	2,963



	Mobile Testing: 50+, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	47
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	3,016
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	30
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	26,646
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	268
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	15,997
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	123
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	51,768
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	764
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	31,457
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	158
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	58,332
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2,621



	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	16,386
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	570
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	60,955
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,375
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	48,498
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	969
	Service Delivery Point (Facility)Other PITC: <1, Negative	7,990
	Service Delivery Point (Facility) Other PITC: <1, Positive	233
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	82,591
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	884
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	234
	Service Delivery Point (Community) Other: 10-14, Female, Positive	3
	Service Delivery Point (Community) Other: 10-14, Male, Negative	179
	Service Delivery Point (Community) Other: 10-14, Male, Positive	1
	Service Delivery Point (Community) Other: 15-19, Female, Negative	1,124
	Service Delivery Point (Community) Other: 15-19, Female, Positive	31
	Service Delivery Point (Community)	688



	Other: 15-19, Male, Negative	
	Service Delivery Point (Community)	1
	Other: 15-19, Male, Positive	
	Service Delivery Point (Community)	1,270
	Other: 20-24, Female, Negative	
	Service Delivery Point (Community)	49
	Other: 20-24, Female, Positive	
	Service Delivery Point (Community)	358
	Other: 20-24, Male, Negative	
	Service Delivery Point (Community)	13
	Other: 20-24, Male, Positive	
	Service Delivery Point (Community)	1,327
	Other: 50+, Female, Negative	
	Service Delivery Point (Community)	50
	Other: 50+, Female, Positive	
	Service Delivery Point (Community)	16,411
	Other: 50+, Male, Negative	
	Service Delivery Point (Community)	14
	Other: 50+, Male, Positive	
	Service Delivery Point (Community)	502
	Other: 1-9, Negative	
	Service Delivery Point (Community)	5
	Other: 1-9, Positive	
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	74
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	14
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	65
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	152
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	72
	Service Delivery Point (Facility) TB:	62



	15-19, Male, Negative	
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	36
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	333
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	73
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	152
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	218
	Service Delivery Point (Facility) TB: 50+, Female, Negative	584
	Service Delivery Point (Facility) TB: 50+, Female, Positive	324
	Service Delivery Point (Facility) TB: 50+, Male, Negative	323
	Service Delivery Point (Facility) TB: 50+, Male, Positive	364
	Service Delivery Point (Facility) TB: 1-9, Negative	268
	Service Delivery Point (Facility) VMC: 10-14, Negative	14,354
	Service Delivery Point (Facility) VMC: 10-14, Positive	291
	Service Delivery Point (Facility) VMC: 15-19, Negative	10,810
	Service Delivery Point (Facility) VMC: 15-19, Positive	221
	Service Delivery Point (Facility) VMC: 20-24, Negative	7,168
	Service Delivery Point (Facility) VMC: 20-24, Positive	148
	Service Delivery Point (Facility)	2



	VMMC: 50+, Negative	
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2,132
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	47
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	2,990
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	32
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	2,958
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	239
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2,653
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	33
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,878
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	495
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	2,363
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	110
	Service Delivery Point (Facility) Index: 50+, Female, Negative	3,007
	Service Delivery Point (Facility) Index: 50+, Female, Positive	679
	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,652
	Service Delivery Point (Facility) Index: 50+, Male, Positive	153
	Service Delivery Point (Facility)	7,385



	Index: 1-9, Negative	
	Service Delivery Point (Facility) Index: 1-9, Positive	106
	By Key Population: People in prisons and other enclosed settings, Negative	757
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	1,200
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	17
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	1,059
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	17
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	8,169
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	197
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	4,175
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	192
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	5,023
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	482
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	2,263
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	198
	Service Delivery Point (Community)	6,814





	Index Mod: 50+, Female, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	95
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	2,571
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	192
	Service Delivery Point (Community) Index Mod: 1-9, Negative	4,821
	Service Delivery Point (Community) Index Mod: 1-9, Positive	43
	Service Delivery Point (Facility) ANC: 10-14, Negative	312
	Service Delivery Point (Facility) ANC: 10-14, Positive	30
	Service Delivery Point (Facility) ANC: 15-19, Negative	9,399
	Service Delivery Point (Facility) ANC: 15-19, Positive	542
	Service Delivery Point (Facility) ANC: 20-24, Negative	9,738
	Service Delivery Point (Facility) ANC: 20-24, Positive	1,313
	Service Delivery Point (Facility) ANC: 50+, Negative	165
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	13
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	7
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	27
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	7
	Service Delivery Point (Facility)	29



	VCT: 20-24, Male, Negative	
	Service Delivery Point (Facility)	4
	VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility)	8
	VCT: 50+, Female, Positive	
	Service Delivery Point (Facility)	2
	VCT: 50+, Male, Positive	
	Service Delivery Point (Facility)	7
	VCT: 1-9, Negative	
	Service Delivery Point (Community)	98
	VCT Mod: 10-14, Female, Negative	
	Service Delivery Point (Community)	1
	VCT Mod: 10-14, Female, Positive	
	Service Delivery Point (Community)	50
	VCT Mod: 10-14, Male, Negative	
	Service Delivery Point (Community)	1
	VCT Mod: 10-14, Male, Positive	
	Service Delivery Point (Community)	576
	VCT Mod: 15-19, Female, Negative	
	Service Delivery Point (Community)	19
	VCT Mod: 15-19, Female, Positive	
	Service Delivery Point (Community)	578
	VCT Mod: 15-19, Male, Negative	
	Service Delivery Point (Community)	694
	VCT Mod: 20-24, Female, Negative	
	Service Delivery Point (Community)	57
	VCT Mod: 20-24, Female, Positive	
	Service Delivery Point (Community)	850
	VCT Mod: 20-24, Male, Negative	
	Service Delivery Point (Community)	11
	VCT Mod: 20-24, Male, Positive	
	Service Delivery Point (Community)	303
	VCT Mod: 50+, Female, Negative	
	Service Delivery Point (Community)	8



VCT Mod: 50+, Female, Positive	
Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	304
Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	7
Service Delivery Point (Community) VCT Mod: 1-9, Negative	80
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	952
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	1,121
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,113
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	357
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	957
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	1,325
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,118
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	483
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	952
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	960
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,113
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	410
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	952
HTS_TST_N_DSD_Index_Age_Sex_Result	882



x_Result 40-49, Female, Positive	
HTS_TST_N_DSD_Index_Age_Sex x_Result 40-49, Male, Negative	1,113
HTS_TST_N_DSD_Index_Age_Sex x_Result 40-49, Male, Positive	472
HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Female, Negative	150
HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Female, Positive	33
HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Male, Negative	65
HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Male, Positive	19
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Negative	151
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Positive	39
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Negative	65
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Positive	26
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Negative	149
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Positive	27
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Negative	66
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Positive	22
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	150
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	26
HTS_TST_N_DSD_Inpat_Age_Sex	65



	_Result 40-49, Male, Negative	
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	25
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	1,872
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	174
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Negative	1,805
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Positive	115
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Negative	1,872
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Positive	203
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Negative	1,805
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Positive	158
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Negative	1,872
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Positive	148
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Male, Negative	1,806
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Male, Positive	133
	HTS_TST_N_DSD_MbMod_Age_	1,863



	Sex_Result 40-49, Female, Negative	
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 40-49, Female, Positive	132
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 40-49, Male, Negative	1,806
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 40-49, Male, Positive	149
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Female, Negative	1,901
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Female, Positive	285
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Male, Negative	1,232
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Male, Positive	497
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Female, Negative	1,901
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Female, Positive	324
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Male, Negative	1,232
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Male, Positive	664
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Female, Negative	1,901
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Female, Positive	239



HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	1,232
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	563
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	1,901
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	207
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	1,232
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	658
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	22,931
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	2,261
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	11,133
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	1,494
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	22,931
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	2,667
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	11,137
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	2,052



HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	22,931
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	1,928
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	11,133
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	1,698
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	22,932
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	1,759
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	11,133
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	1,986
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	499
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	34
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	243
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	27
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	499
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	41





	Positive	
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	243
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	38
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	499
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	30
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	243
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	31
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	499
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	28
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	243
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	38
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	4,087
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	610
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	4,528



HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	723
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	4,087
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	526
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,443
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	482
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	286
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	514
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	181
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	478
HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	285
HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	606
HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	180
HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	667
HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	285
HTS_TST_N_DSD_TBC_Age_Sex	434



	_Result 35-39, Female, Positive	
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Negative	181
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	557
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	285
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	401
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	181
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	631
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	84
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	10
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	56
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	6
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	35
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	40
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Negative	352
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Positive	44
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Negative	506
	HTS_TST_N_DSD_VCTMod_Age_	17



	Sex_Result 25-29, Male, Positive	
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	352
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	50
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	506
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	23
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	352
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	36
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	506
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	19
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	352
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	33
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	506
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	22
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	3,599
	HTS_TST_N_DSD_VMMC_Age_S	76



	ex_Result 25-29, Male, Positive	
GEND_GBV_DSD	Number of people receiving post-GBV care	2,693
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3
	By type of service: Sexual Violence (Post-Rape Care)	0
	By PEP service provision (related to sexual violence services provided)	0
	<10, Female, Physical and/or Emotional Violence	0
	<10, Female, Sexual Violence (Post-Rape Care)	182
	<10, Male, Sexual Violence (Post-Rape Care)	74
	10-14, Female, Physical and/or Emotional Violence	0
	10-14, Female, Sexual Violence (Post-Rape Care)	218
	10-14, Male, Sexual Violence (Post-Rape Care)	85
	15-19, Female, Physical and/or Emotional Violence	0
	15-19, Female, Sexual Violence (Post-Rape Care)	635
	15-19, Male, Sexual Violence (Post-Rape Care)	121
	20-24, Female, Physical and/or Emotional Violence	319
	20-24, Female, Sexual Violence (Post-Rape Care)	233
20-24, Male, Sexual Violence	72	



	(Post-Rape Care)	
	50+, Female, Physical and/or Emotional Violence	317
	50+, Female, Sexual Violence (Post-Rape Care)	94
	50+, Male, Sexual Violence (Post-Rape Care)	36
	Unknown Age, Female, Physical and/or Emotional Violence	0
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	69
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	94
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	0
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	59
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	82
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	0
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	86



	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	101
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	0
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	108
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	113
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	90,214
	Age/Sex: 10-14 Male	5,636
	Age/Sex: 15-17 Male	4,514
	By: Age/sex: Male 18-24	1,838
	By: Age/sex: Male 25+	3,473
	Age/Sex: 10-14 Female	14,234
	Age/Sex: 15-17 Female	14,716
	By: Age/sex: 18-24 Female	10,505
	By: Age/sex: 25+ Female	19,808
	Sum of Age/Sex disaggregates	39,100
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	4,539
	Required only for DREAMS countries - By service, age and	3,284



	sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	890
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	348
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	4,749
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	4,053
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	908
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	154
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	4,808
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	3,272
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	1,101
	Required only for DREAMS	7,148





	countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	368
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	284
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	374
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	927
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	7,622
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	4,615
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	4,025
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	95
	Required only for DREAMS	971



	countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	612
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	238
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	78
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	2,768
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	3,032
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1,973
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	8,948
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	74



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	74
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	1,479
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	3,125
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	2,124
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	954
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	5,195
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	2,742
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	2,165
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	759
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	1,657
	Age/Sex: <1	1,727
	Age/Sex: 1-9	13,607
	Program Completion: Active	87,643



	Program Completion: Graduation	2,571
	Program Completion: Transferred	0
	Program Completion: Exited without graduation	0
	OVC_SERV_N_DSD_Age_Sex_Service_v4 <1, Unknown Sex, Economic Strengthening	0
	OVC_SERV_N_DSD_Age_Sex_Service_v4 <1, Unknown Sex, Education Support	0
	OVC_SERV_N_DSD_Age_Sex_Service_v4 <1, Unknown Sex, Other Service Areas	0
	OVC_SERV_N_DSD_Age_Sex_Service_v4 <1, Unknown Sex, Parenting/Caregiver Programs	0
	OVC_SERV_N_DSD_Age_Sex_Service_v4 <1, Unknown Sex, Social Protection	0
	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Economic Strengthening	0
	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Education Support	0
	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Other Service Areas	0
	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Parenting/Caregiver Programs	0
	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	0
OVC_SERV_TA	Number of active beneficiaries	2



	served by PEPFAR OVC programs for children and families affected by HIV/AIDS	
	Age/Sex: 10-14 Male	0
	Age/Sex: 15-17 Male	1
	By age/sex: 18-24 Male	1
	By age/sex: 25+ Male	1
	Age/Sex: 10-14 Female	0
	Age/Sex: 15-17 Female	0
	By age/sex: 18-24 Female	0
	By age/sex: 25+ Female	0
	Sum of Age/Sex disaggregates	1
	Age/Sex: <1	1
	Age/Sex: 1-9	0
	Program Completion: Active	1
	Program Completion: Graduated	1
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	54 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	48,817
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	90,214
OVC_HIVSTAT_TA	OVC_HIVSTAT_TA Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	15,900 %



	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	318
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	10,831
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	175
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6,544
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	108



	ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,004
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	85 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	39,671
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	46,653
	By Age/Sex (Denominator): <15, Female	2,649
	By Age/Sex (Denominator): <15, Male	3,116
	By Age/Sex (Denominator): 15+, Female	28,624
	By Age/Sex (Denominator): 15+, Male	12,264
	By Age/Sex (Numerator): <15,	2,234



	Female	
	By Age/Sex (Numerator): <15, Male	2,627
	By Age/Sex (Numerator): 15+, Female	24,372
	By Age/Sex (Numerator): 15+, Male	10,438
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	46,653
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	39,671
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	302,035
	Denominator: By Aggregated Age/Sex: <15, Female	6,885
	Denominator: By Aggregated Age/Sex: <15, Male	6,640
	Denominator: By Aggregated Age/Sex: 15+, Female	182,380
	Denominator: By Aggregated Age/Sex: 15+, Male	106,130
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	15,101
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	15,101





	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	252,651
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	4,531
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	44,098
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	677
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	12,227
	By infants who received a virologic test within 2 months of birth	11,616
	By infants who received their first virologic HIV test between 2 and 12 months of age	611
	Sum of Infant Age disaggregates	12,227
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	302,106
	Age/Sex: 15-19 Male	3,618
	Age/Sex: 15-19 Female	5,868
	Age/Sex: <1	777
	Age/Sex: <1-9	7,184



	Age/Sex: 10-14 Male	2,378
	Age/Sex: 10-14 Female	2,119
	Age/Sex: 20-24 Male	9,515
	Age/Sex: 50+ Male	22,127
	Age/Sex: 20-24 Female	17,371
	Age/Sex: 50+ Female	35,237
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	28,832
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	20,888
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	34,695
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	23,868
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	23,473
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	19,648
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	25,993
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	18,515
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	45,260
	By Age/Sex: <1	95
	By Age/Sex: 1-9	1,144
	By Age/Sex: 10-14 Male	365
	By Age/Sex: 15-19 Male	435
	By Age/Sex: 20-24 Male	1,304
	By Age/Sex: 50+ Male	2,697
	By Age/Sex: 10-14 Female	350
	By Age/Sex: 15-19 Female	869



	By Age/Sex: 20-24 Female	2,721
	By Age/Sex: 50+ Female	4,651
	Pregnancy status	3,478
	FSW	433
	MSM	433
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	5,964
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	3,034
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	5,364
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	3,148
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	3,089
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	3,380
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	3,834
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	2,816
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	292,759
	Denominator: Aggregate Age/Sex	5,187



	by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	109,779
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	5,187
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	172,606
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	95 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	86,035
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	90,595
	Numerator by Status: Pregnant	11,662
	Denominator by Status: Pregnant	12,258
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	657
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28,333
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and	629



	children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	56,416
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	678
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29,844
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	657
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	59,416

Approved



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	--	--



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7455	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense		
11018	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	152,851
11030	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	150,000
14301	Population Services International	NGO	U.S. Agency for International Development		
16768	Mothers 2 Mothers	NGO	U.S. Agency for International Development		
17123	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	550,000
17401	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	13,800,355



17429	Population Services International	NGO	U.S. Department of Defense		
17431	University Research Corporation, LLC	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,184,432
17432	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,090,527
17549	JHPIEGO	University	U.S. Agency for International Development	GHP-State	7,077,418
18020	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	19,551,210
18048	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	2,000,000
18143	Catholic Relief Services	FBO	U.S. Agency for International Development		
18227	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,901,670





18235	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State	502,463
18240	Vodafone Foundation	NGO	U.S. Agency for International Development		
18524	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18525	Baylor College of Medicine Children's Foundation	University	U.S. Agency for International Development	GHP-State	300,000
18641	Mothers 2 Mothers	NGO	U.S. Agency for International Development	GHP-State	2,683,306
18643	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development		
70159	TBD	TBD	Redacted	Redacted	Redacted
70166	FHI 360	NGO	U.S. Agency for International Development	GHP-State	653,628
70167	TBD	TBD	Redacted	Redacted	Redacted



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 7455</b>	<b>Mechanism Name: LDF, Department of Defense Support</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	7455	
<b>Mechanism Name:</b>	LDF, Department of Defense Support	
<b>Prime Partner Name:</b>	U.S. Department of Defense (Defense)	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 11018</b>	<b>Mechanism Name: Peace Corps</b>
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 152,851</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 34,291</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 187,142</b>	
Funding Source	Funding Amount
GHP-State	152,851



**Cross-Cutting Budget Attribution(s)**

Gender: GBV	10,250
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	10,250
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Education	10,250
Water	10,000

**Budget Code Information**

<b>Mechanism ID: 11018</b> <b>Mechanism Name: Peace Corps</b> <b>Prime Partner Name: U.S. Peace Corps</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	126,642
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	26,209
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,574
PP_PREV_DSD	Age/sex: 10-14 Male	883
PP_PREV_DSD	Age/sex: 15-19 Male	995
PP_PREV_DSD	Age/sex: 20-24 Male	404
PP_PREV_DSD	Age/sex: 50+ Male	67
PP_PREV_DSD	Age/sex: 10-14 Female	1,463
PP_PREV_DSD	Age/sex: 15-19 Female	1,285
PP_PREV_DSD	Age/sex: 20-24 Female	477
PP_PREV_DSD	Sum of Age/Sex disaggregates	5,574
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,637
OVC_SERV_DSD	Age/Sex: 10-14 Male	523
OVC_SERV_DSD	Age/Sex: 15-17 Male	681
OVC_SERV_DSD	By: Age/sex: Male 18-24	354
OVC_SERV_DSD	By: Age/sex: Male 25+	213
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,145



OVC_SERV_DSD	Age/Sex: 15-17 Female	1,313
OVC_SERV_DSD	By: Age/sex: 18-24 Female	776
OVC_SERV_DSD	By: Age/sex: 25+ Female	215
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,662
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	197
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	47
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	145
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	230
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	131
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	112
OVC_SERV_DSD	Age/Sex: <1	15
OVC_SERV_DSD	Age/Sex: 1-9	357
OVC_SERV_DSD	Program Completion: Active	5,576
OVC_SERV_DSD	Program Completion: Graduation	61
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	934
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,637

### Implementing Mechanism Details

<b>Mechanism ID: 11030</b>	<b>Mechanism Name: PEPFAR Small Grants Program</b>
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No





Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 150,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 150,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	30,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Education	50,000
Food and Nutrition: Policy, Tools, and Service Delivery	100,000

**Budget Code Information**

<b>Mechanism ID: 11030</b>		
<b>Mechanism Name: PEPFAR Small Grants Program</b>		
<b>Prime Partner Name: U.S. Department of State</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	60,000



Strategic Area	Budget Code	Planned Amount
Care	HKID	30,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	60,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2019
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	903
OVC_SERV_TA	Age/Sex: 10-14 Male	78
OVC_SERV_TA	Age/Sex: 15-17 Male	69
OVC_SERV_TA	By age/sex: 18-24 Male	56
OVC_SERV_TA	By age/sex: 25+ Male	61
OVC_SERV_TA	Age/Sex: 10-14 Female	89
OVC_SERV_TA	Age/Sex: 15-17 Female	78
OVC_SERV_TA	By age/sex: 18-24 Female	83
OVC_SERV_TA	By age/sex: 25+ Female	188
OVC_SERV_TA	Sum of Age/Sex disaggregates	314



OVC_SERV_TA	Age/Sex: <1	7
OVC_SERV_TA	Age/Sex: 1-9	163
OVC_SERV_TA	Program Completion: Active	872
OVC_SERV_TA	Program Completion: Graduated	31
OVC_HIVSTAT_TA	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	467
OVC_HIVSTAT_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	903

**Implementing Mechanism Details**

<b>Mechanism ID: 14301</b>	<b>Mechanism Name: LETLAMA</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	<b>14301</b>
----------------------	--------------



<b>Mechanism Name: LETLAMA</b>		
<b>Prime Partner Name: Population Services International</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16768</b>	<b>Mechanism Name: Mentor Mothers Reducing Infections Through Support and Education (RISE)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Mothers 2 Mothers	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	16768	
<b>Mechanism Name:</b>	Mentor Mothers Reducing Infections Through Support and Education (RISE)	
<b>Prime Partner Name:</b>	Mothers 2 Mothers	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount





Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17123</b>	<b>Mechanism Name: CDC HMIS support to the MOH</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 550,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 830,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,380,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	550,000

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	75,000
----------------------------	--------

### Budget Code Information



<b>Mechanism ID:</b> 17123 <b>Mechanism Name:</b> CDC HMIS support to the MOH <b>Prime Partner Name:</b> Columbia University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	550,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17401</b>	<b>Mechanism Name: Strengthening Tuberculosis and HIV Response in Lesotho (STAR-L)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 13,800,355</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 13,800,355</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	13,800,355

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	120,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Water	200,000
Human Resources for Health	150,000
Motor Vehicles: Purchased	110,283
Food and Nutrition: Policy, Tools, and Service Delivery	50,000

**Budget Code Information**

<b>Mechanism ID:</b>	17401	
<b>Mechanism Name:</b>	Strengthening Tuberculosis and HIV Response in Lesotho (STAR-L)	
<b>Prime Partner Name:</b>	Elizabeth Glaser Pediatric AIDS Foundation	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	905,544
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	1,811,088
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	129,363
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,922,478
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	443,078
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	180,181
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	8,020,533
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	388,090
-----------	------	---------

## Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,810
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,766
PMTCT_ART_DSD	New on ART	1,461
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,349
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,766
PMTCT_STAT_DSD	Number of new ANC and L&D clients	19,743
PMTCT_STAT_DSD	By Age (Denominator): 10-14	147
PMTCT_STAT_DSD	By Age (Denominator): <15-19	4,157
PMTCT_STAT_DSD	By Age (Denominator): 20-24	6,304
PMTCT_STAT_DSD	By Number of known positives: 15-19	232
PMTCT_STAT_DSD	By Number of known positives: 20-24	722
PMTCT_STAT_DSD	By Number of new positives: 15-19	262
PMTCT_STAT_DSD	By Number of new positives: 20-24	460
PMTCT_STAT_DSD	By Number of new negative: 10-14	157
PMTCT_STAT_DSD	By Number of new negative: 15-19	3,454
PMTCT_STAT_DSD	By Number of new negative: 20-24	4,792
PMTCT_STAT_DSD	By Age (Numerator): 10-14	145
PMTCT_STAT_DSD	By Age (Numerator): 15-19	3,945
PMTCT_STAT_DSD	By Age (Numerator): 20-24	5,988
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	4,159
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	2,721



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	1,947
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	308
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	475
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	2,835
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	646
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	1,031
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	1,342
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	209
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	530
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,113
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	204
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	159
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	143
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	3,954
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	2,585
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,850
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	299
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,589
PrEP_NEW_DSD	Male 15-19	91
PrEP_NEW_DSD	Male 20-24	92
PrEP_NEW_DSD	Male 50+	118





PrEP_NEW_DSD	Female 15-19	143
PrEP_NEW_DSD	Female 20-24	146
PrEP_NEW_DSD	Female 50+	232
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	125
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	72
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	110
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	76
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	106
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	83
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	111
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	84
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	629
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	229,389
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	55
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	89
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24,	9



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	147
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	80
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	364
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	9,188
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	5,514
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	17,833
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	262
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	10,838
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	20,100
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	907
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	5,646



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	195
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	21,005
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	472
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	16,706
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	331
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	2,753
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	83
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	28,479
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	301
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	26



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	218
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	122
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	122
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	132
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	728
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,026
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,017
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	85
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	915
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	649
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	175
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	811



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,033
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	229
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	567
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	2,528
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	132
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	3,949
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	229
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	4,091
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	552
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	75
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	321
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	380
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	377
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	121
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	321
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	451
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34,	377



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	170
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	321
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	325
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	377
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	141
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	321
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	301
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	377
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	164
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	11



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	59
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	7,903
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	779
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	3,837
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	515
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	7,903
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	923
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	3,837
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	705
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39,	7,903



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	667
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	3,837
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	588
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	7,903
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	608
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	3,837
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	688
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	1,715
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	255
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,900
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	303
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,715
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	223
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,027
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	202
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29,	194





	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	179
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	223
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	251
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	163
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	210
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	147
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	234
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,768
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,768
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of	126



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,452
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	132
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,058
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	126
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,455
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	126
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,061
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,035
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	72
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,433
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The	38



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,492
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,814
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	4,572
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	242
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,814
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	112,642
TX_CURR_DSD	Age/Sex: 15-19 Male	1,647
TX_CURR_DSD	Age/Sex: 15-19 Female	2,228
TX_CURR_DSD	Sum of age/sex disaggregates	3,875
TX_CURR_DSD	Age/Sex: <1	280
TX_CURR_DSD	Age/Sex: <1-9	2,793
TX_CURR_DSD	Age/Sex: 10-14 Male	903
TX_CURR_DSD	Age/Sex: 10-14 Female	808
TX_CURR_DSD	Age/Sex: 20-24 Male	4,210
TX_CURR_DSD	Age/Sex: 50+ Male	8,262
TX_CURR_DSD	Age/Sex: 20-24 Female	6,480
TX_CURR_DSD	Age/Sex: 50+ Female	14,645
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	8,007
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	10,614
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	9,776



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	10,027
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	9,461
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	6,272
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	10,352
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	5,877
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	15,555
TX_NEW_DSD	By Age/Sex: <1	36
TX_NEW_DSD	By Age/Sex: 1-9	469
TX_NEW_DSD	By Age/Sex: 10-14 Male	156
TX_NEW_DSD	By Age/Sex: 15-19 Male	148
TX_NEW_DSD	By Age/Sex: 20-24 Male	439
TX_NEW_DSD	By Age/Sex: 50+ Male	888
TX_NEW_DSD	By Age/Sex: 10-14 Female	144
TX_NEW_DSD	By Age/Sex: 15-19 Female	299
TX_NEW_DSD	By Age/Sex: 20-24 Female	889
TX_NEW_DSD	By Age/Sex: 50+ Female	1,627
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,590
TX_NEW_DSD	Pregnancy status	1,461
TX_NEW_DSD	FSW	148
TX_NEW_DSD	MSM	148
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,096
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,149
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,584
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,097



	Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,075
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,098
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,472
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	889
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	109,403
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,936
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	41,019
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,936
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	64,512
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	32,180
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	33,872
TX_RET_DSD	Numerator by Status: Pregnant	4,372
TX_RET_DSD	Denominator by Status: Pregnant	4,598
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	248
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,607



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	233
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21,092
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	256
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,163
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	248
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22,205
HTS_SELF_DSD	HTS_SELF_N_DSD	28,625
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	197
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	159
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	0



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1,756
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	316
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	1,078
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	419
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	2,999
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	6,223
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	1,784
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	408
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	1,408
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	691
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	1,631
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	522
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1,378
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	656
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	1,566
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	554
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1,348



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	618
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	1,482
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	413
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1,269
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	498
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	1,570
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	410
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	667
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	496
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Female, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Female, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Male, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Male, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	22,636
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	5,989
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	5,848





HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	392
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	14,377
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	16,909
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	942
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,113
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	10,421
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	4,433
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	790
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	942
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	8,870
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	3,775
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	16,909
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	14,377
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	112,628
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,570
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,478
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	67,989
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	39,591
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	5,637



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	5,637
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	95,382
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,691
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	15,323
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	232

### Implementing Mechanism Details

<b>Mechanism ID: 17429</b>	<b>Mechanism Name: LDF Comprehensive Clinical Support Program</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information



<b>Mechanism ID: 17429</b>		
<b>Mechanism Name: LDF Comprehensive Clinical Support Program</b>		
<b>Prime Partner Name: Population Services International</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17431</b>	<b>Mechanism Name: Support Laboratory Diagnosis and Monitoring to Scale up and Improve HIV/AIDS Care and Treatment Services in the Kingdom of Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,184,432</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,184,432</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,184,432

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	275,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID:</b> <b>Mechanism Name:</b> <b>Prime Partner Name:</b>	<b>17431</b> <b>Support Laboratory Diagnosis and Monitoring to Scale up and Improve HIV/AIDS Care and Treatment Services in the Kingdom of Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)</b> <b>University Research Corporation, LLC</b>	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HVTB	57,955
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	14,489
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	460,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	630,255
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	21,733

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17432</b>	<b>Mechanism Name: Support Ministry of Health to Strengthen Health Systems and Coordinate HIV/AIDS Prevention, Care and Treatment Programs in the Kingdom of Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ministry of Health (MOH)		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	
<b>Total All Funding Sources: 7,090,527</b>		<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 451,312</b>		
<b>Total All Funding Sources and Applied Pipeline Amount: 7,541,839</b>		



Funding Source	Funding Amount
GHP-State	7,090,527

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	300,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID:</b>	17432	
<b>Mechanism Name:</b>	Support Ministry of Health to Strengthen Health Systems and Coordinate HIV/AIDS Prevention, Care and Treatment Programs in the Kingdom of Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)	
<b>Prime Partner Name:</b>	Ministry of Health (MOH)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	265,657
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	597,727
Strategic Area	Budget Code	Planned Amount
Care	PDCS	398,485
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	367,912
Strategic Area	Budget Code	Planned Amount





Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	81,200
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	66,414
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	5,113,890



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	199,242

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17549</b>	<b>Mechanism Name: TSEPO</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 7,077,418</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 648,328</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 7,725,746</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	7,077,418

### Cross-Cutting Budget Attribution(s)

Gender: GBV	5,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Adolescent Girls and Young Women (AGYW)	1,724,736



**Budget Code Information**

<b>Mechanism ID:</b> 17549 <b>Mechanism Name:</b> TSEPO <b>Prime Partner Name:</b> JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	5,169,914
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	1,907,504
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	36,219
VMMC_CIRC_DSD	By Age: 10-14	14,488
VMMC_CIRC_DSD	By Age: 15-19	10,865
VMMC_CIRC_DSD	By Age: 20-24	7,244



VMMC_CIRC_DSD	By Age: 25-29	3,622
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	32,597
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	36,219
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	36,040
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	179
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	6,808
PrEP_NEW_DSD	Male 15-19	390
PrEP_NEW_DSD	Male 20-24	393
PrEP_NEW_DSD	Male 50+	511
PrEP_NEW_DSD	Female 15-19	608
PrEP_NEW_DSD	Female 20-24	634
PrEP_NEW_DSD	Female 50+	843
PrEP_NEW_DSD	FSW	513
PrEP_NEW_DSD	MSM	1,043
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	547
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	330
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	506
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	359
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	476
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	366
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	476
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	369
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	20
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	36,279
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	14,196
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	291
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19,	10,647



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	218
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	7,100
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	3,549
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	74
HTS_SELF_DSD	HTS_SELF_N_DSD	860
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	55
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	40
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	94
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	65
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	15



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	58
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	52
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	41
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	52
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	41
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	54
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	13



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	683
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	177
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	166
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	11

**Implementing Mechanism Details**

<b>Mechanism ID: 18020</b>	<b>Mechanism Name: Providing Universal Services for HIV/AIDS (PUSH)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 19,551,210</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 19,551,210</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	19,551,210

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	15,000
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	60,000





Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Sub Area:	Capacity building
Human Resources for Health	1,000,000
Food and Nutrition: Policy, Tools, and Service Delivery	250,000
Water	300,000
Motor Vehicles: Purchased	150,000

**Budget Code Information**

<b>Mechanism ID:</b> 18020		
<b>Mechanism Name:</b> Providing Universal Services for HIV/AIDS (PUSH)		
<b>Prime Partner Name:</b> Elizabeth Glaser Pediatric AIDS Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	1,951,610
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	3,558,645
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	259,730



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	2,040,740
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	722,924
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	296,746
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	9,768,918
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	951,897

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	7,417
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,905
PMTCT_ART_DSD	New on ART	2,017
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	5,400
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,905
PMTCT_STAT_DSD	Number of new ANC and L&D clients	30,317
PMTCT_STAT_DSD	By Age (Denominator): 10-14	62
PMTCT_STAT_DSD	By Age (Denominator): <15-19	6,433
PMTCT_STAT_DSD	By Age (Denominator): 20-24	9,880
PMTCT_STAT_DSD	By Number of known positives: 15-19	277
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,267
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	147
PMTCT_STAT_DSD	By Number of new positives: 20-24	1,041
PMTCT_STAT_DSD	By Number of new positives: 50+	1



PMTCT_STAT_DSD	By Number of new negative: 10-14	47
PMTCT_STAT_DSD	By Number of new negative: 15-19	5,693
PMTCT_STAT_DSD	By Number of new negative: 20-24	7,068
PMTCT_STAT_DSD	By Number of new negative: 50+	84
PMTCT_STAT_DSD	By Age (Numerator): 10-14	60
PMTCT_STAT_DSD	By Age (Numerator): 15-19	6,109
PMTCT_STAT_DSD	By Age (Numerator): 20-24	9,387
PMTCT_STAT_DSD	By Age (Numerator): 50+	87
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	6,576
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	4,687
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,025
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	654
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,474
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	4,158
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	631
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	1,568
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,674
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	222
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	641
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,076
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	209
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	280
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	305



	40-49, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	41
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	6,248
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	4,457
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,927
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	630
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	4,032
PrEP_NEW_DSD	Male 15-19	233
PrEP_NEW_DSD	Male 20-24	237
PrEP_NEW_DSD	Male 50+	303
PrEP_NEW_DSD	Female 15-19	361
PrEP_NEW_DSD	Female 20-24	372
PrEP_NEW_DSD	Female 50+	531
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	322
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	185
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	283
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	199
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	279
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	220
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	285
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	222
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	1,605
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	425,740
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	14



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	133
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	189
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	216
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	88
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	638
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	17,440
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	170
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	10,471
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	83



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	33,875
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	500
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	20,583
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	38,165
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,709
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	10,721
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	374
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	39,880
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	900
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	31,736
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	636
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	5,232
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	149
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	54,061
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	577
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	47



HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	95
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	206
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	132
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	365
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	200
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	200
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	231
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	165
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,390
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,944





HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,925
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	153
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,724
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,219
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	318
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,539
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	76
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,958
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	447
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,076
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	98
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	4,809
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	61
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	757
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	180
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	5,450
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	313



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	5,647
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	761
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	90
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	626
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	736
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	730
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	235
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	626
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	869
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	730
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	311
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	626
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	631
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	730
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	267
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	626
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	577
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	730
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	306



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	89
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	89
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	89
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	89
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29,	15,002



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	1,477
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	7,283
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	976
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	15,002
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	1,738
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	7,283
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	1,342
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	15,002
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	1,257
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	7,283
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	1,106
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	15,002
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	1,147
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	7,283
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	1,294
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,372
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29,	355



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,628
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	420
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,372
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	303
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,416
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	280
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	320
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	107
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	299
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	382
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	107
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	416
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	271
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	107



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	346
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	253
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	107
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	396
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	9,612
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	9,612
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	207
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,758
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	221
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,426
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	212
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5,756
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total	212



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,432
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	6,727
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	102
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,070
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	69
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,486
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7,413
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	7,044
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	369
PMTCT_EID_DSD	Sum of Infant Age disaggregates	7,413
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	187,679
TX_CURR_DSD	Age/Sex: 15-19 Male	1,953
TX_CURR_DSD	Age/Sex: 15-19 Female	3,604



TX_CURR_DSD	Sum of age/sex disaggregates	5,557
TX_CURR_DSD	Age/Sex: <1	497
TX_CURR_DSD	Age/Sex: <1-9	4,391
TX_CURR_DSD	Age/Sex: 10-14 Male	1,475
TX_CURR_DSD	Age/Sex: 10-14 Female	1,311
TX_CURR_DSD	Age/Sex: 20-24 Male	5,251
TX_CURR_DSD	Age/Sex: 50+ Male	13,758
TX_CURR_DSD	Age/Sex: 20-24 Female	10,784
TX_CURR_DSD	Age/Sex: 50+ Female	20,396
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	20,664
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	10,149
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	24,723
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	13,627
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	13,816
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	13,322
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	15,445
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	12,513
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	29,536
TX_NEW_DSD	By Age/Sex: <1	59
TX_NEW_DSD	By Age/Sex: 1-9	675
TX_NEW_DSD	By Age/Sex: 10-14 Male	209
TX_NEW_DSD	By Age/Sex: 15-19 Male	285
TX_NEW_DSD	By Age/Sex: 20-24 Male	860
TX_NEW_DSD	By Age/Sex: 50+ Male	1,799





TX_NEW_DSD	By Age/Sex: 10-14 Female	206
TX_NEW_DSD	By Age/Sex: 15-19 Female	567
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,822
TX_NEW_DSD	By Age/Sex: 50+ Female	3,005
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,753
TX_NEW_DSD	Pregnancy status	2,017
TX_NEW_DSD	FSW	285
TX_NEW_DSD	MSM	285
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,853
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,873
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,761
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,031
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,995
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,277
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,342
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,917
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	182,285
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	3,230
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	68,341
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,230
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	107,484



	Female Routine	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	53,612
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	56,437
TX_RET_DSD	Numerator by Status: Pregnant	7,290
TX_RET_DSD	Denominator by Status: Pregnant	7,660
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	409
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,666
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	396
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35,141
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	422
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18,588
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	409



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	37,018
HTS_SELF_DSD	HTS_SELF_N_DSD	38,628
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	292
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	241
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	11
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	2,618
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	460
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	1,596
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	614
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	4,359
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	898
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	2,551
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	617
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	2,064
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	1,038



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	2,368
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	782
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	2,027
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	989
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	2,192
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	715
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1,892
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	834
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	2,154
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1,840
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	740
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	2,144
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	590
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	864
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male,	501



	Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Female, Directly-Assisted	29
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Female, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Male, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	29,964
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	8,664
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	8,266
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	567
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	23,956
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	28,169
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,565
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,861
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	17,353
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	7,390
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,324
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,565



TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	14,779
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	6,288
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	28,169
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	23,956
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	187,657
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	4,280
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	4,127
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	113,289
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	65,961
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	9,376
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	9,376
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	155,808
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	2,814
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	28,594
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	441

### Implementing Mechanism Details

<b>Mechanism ID: 18048</b>	<b>Mechanism Name: Global Health Supply Chain Management</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
<b>Total All Funding Sources: 1,989,055</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,989,055</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	1,989,055

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	250,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID: 18048</b>		
<b>Mechanism Name: Global Health Supply Chain Management</b>		
<b>Prime Partner Name: Global Health Supply Chain Program</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	135,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	500,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount





Treatment	HTXS	1,230,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	135,000

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18143</b>	<b>Mechanism Name: 4Children – Coordinating Comprehensive Care for Children</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 18143</b>
----------------------------



<b>Mechanism Name:</b> 4Children – Coordinating Comprehensive Care for Children <b>Prime Partner Name:</b> Catholic Relief Services		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18227</b>	<b>Mechanism Name: Scaling-up Targeted Community Based HTS and Linkage to Treatment in Lesotho</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 7,901,670</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 392,699</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 8,294,369</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	7,901,670

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	150,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Human Resources for Health	300,000
Adolescent Girls and Young Women (AGYW)	2,916,156

**Budget Code Information**

<b>Mechanism ID:</b>	18227	
<b>Mechanism Name:</b>	Scaling-up Targeted Community Based HTS and Linkage to Treatment in Lesotho	
<b>Prime Partner Name:</b>	Population Services International	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	7,901,670



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	119,158
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	2,438
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	1,996
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	16



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	8,840
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	93
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	4,824
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	3,459
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	264
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,185
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	146
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	2,281
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	2,915
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	47
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	2,956
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	234
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Negative	179



HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	1,124
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	688
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	1,270
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	49
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	358
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	1,327
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	16,411
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	502
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	1,197
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14,	1,056





	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	8,162
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	196
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	4,172
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	191
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	5,019
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	482
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	2,261
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	198
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	6,809
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	2,569
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	192
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	4,809
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	41
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	98
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14,	1



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	50
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	576
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	578
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	694
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	850
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	303
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	304
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	80
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	1,842
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	169
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29,	1,776



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	1,842
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	199
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,776
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	154
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1,842
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	146
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	1,777
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	132
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1,842
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	132
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	1,777
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	149
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,899
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	283
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	1,231
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	496



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	1,899
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	321
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	1,231
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	663
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	1,899
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	239
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	1,231
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	563
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	1,899
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	207
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	1,231
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	658
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	499
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34,	499



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	499
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	499
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	352
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	506
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	352
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	50



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	506
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	352
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	506
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	352
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	506
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	22
HTS_SELF_DSD	HTS_SELF_N_DSD	126,396
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	1,163
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	738
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	30
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	8,840
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	1,554



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	5,350
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	2,059
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	14,677
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	2,954
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	8,480
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2,053
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	6,937
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	3,483
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	7,881
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	2,596
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	6,781
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	3,313
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	7,349
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	2,446
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	6,321
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	2,782
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	7,203



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	1,992
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	6,145
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	2,640
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	7,377
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	1,992
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	2,852
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	85
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	1,687
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	85
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Female, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Female, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Male, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Male, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	96,418
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	29,978
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	26,848
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	1,894

### Implementing Mechanism Details





<b>Mechanism ID: 18235</b>	<b>Mechanism Name: EQUIP</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18235</b> <b>Mechanism Name: EQUIP</b> <b>Prime Partner Name: Right To Care, South Africa</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	502,463
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18240</b>	<b>Mechanism Name: Vodafone</b>
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Vodafone Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18240 <b>Mechanism Name:</b> Vodafone <b>Prime Partner Name:</b> Vodafone Foundation		
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18524</b>	<b>Mechanism Name: ICAP Global Technical Assistance</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18524		
<b>Mechanism Name:</b> ICAP Global Technical Assistance		
<b>Prime Partner Name:</b> Columbia University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18525</b>	<b>Mechanism Name: Technical Support Project (TSP) Regional Program</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine Children's Foundation	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 300,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18525	
<b>Mechanism Name:</b>	Technical Support Project (TSP) Regional Program	
<b>Prime Partner Name:</b>	Baylor College of Medicine Children's Foundation	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount





Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	300,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18641</b>	<b>Mechanism Name: RISE II</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Mothers 2 Mothers	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,683,306</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,683,306</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,683,306

### Cross-Cutting Budget Attribution(s)

Gender: GBV	40,000
Focus Area:	Post GBV Care
Sub Area:	Implementation
Gender: Gender Equality	50,000



Focus Area:	Equity in HIV prevention, care, treatment and support
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Human Resources for Health	300,000
Water	40,000

**Budget Code Information**

<b>Mechanism ID: 18641</b> <b>Mechanism Name: RISE II</b> <b>Prime Partner Name: Mothers 2 Mothers</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	2,683,306
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18643</b>	<b>Mechanism Name: AIDSFREE</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	
<b>Total Mechanism Pipeline: N/A</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 18643</b>		
<b>Mechanism Name: AIDSFREE</b>		
<b>Prime Partner Name: John Snow Inc (JSI)</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 70159</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 70166</b>	<b>Mechanism Name: LINKAGES</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	1,676
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	3,351
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	150,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	200,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Condom programming	1,676
Adolescent Girls and Young Women (AGYW)	288,863





**Budget Code Information**

<b>Mechanism ID: 70166</b> <b>Mechanism Name: LINKAGES</b> <b>Prime Partner Name: FHI 360</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	153,628
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	500,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,599



<p>KP_PREV_DSD</p>	<p>By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>4,131</p>
<p>KP_PREV_DSD</p>	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>2,468</p>

**Implementing Mechanism Details**

<p><b>Mechanism ID: 70167</b></p>	<p><b>TBD: Yes</b></p>
<p><b>REDACTED</b></p>	



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services			141,400	141,400	0	141,400
ICASS			1,642,378	1,642,378	0	1,642,378
Management Meetings/Professional Development			177,888	177,888	0	177,888
Non-ICASS Administrative Costs			60,755	60,755	0	60,755
Staff Program Travel		0	236,732	236,732	0	236,732
USG Staff Salaries and Benefits - Internationally Recruited		0	1,961,123	1,961,123	0	1,961,123
USG Staff Salaries and Benefits - Locally Recruited			190,669	190,669	0	190,669
<b>Total</b>	<b>0</b>	<b>0</b>	<b>4,410,945</b>	<b>4,410,945</b>	<b>0</b>	<b>4,410,945</b>



### U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		2,000		2,000	0	2,000
ICASS		20,983		20,983	10,150	31,133
Management Meetings/Professional Development		3,814		3,814	3,000	6,814
Non-ICASS Administrative Costs		1,353		1,353	2,000	3,353
Staff Program Travel		9,934		9,934	3,353	13,287
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		29,798		29,798	20,202	50,000
<b>Total</b>	<b>0</b>	<b>67,882</b>	<b>0</b>	<b>67,882</b>	<b>38,705</b>	<b>106,587</b>

### U.S. Department of Health and Human Services/Centers for Disease Control and



## Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		232,577		232,577	0	232,577
Computers/IT Services		85,079		85,079	0	85,079
ICASS		517,242		517,242	0	517,242
Management Meetings/Professional Development		37,112		37,112	0	37,112
Non-ICASS Administrative Costs		34,300		34,300	0	34,300
Staff Program Travel		200,408		200,408	0	200,408
USG Staff Salaries and Benefits - Internationally Recruited	512,500	1,238,767		1,751,267	0	1,751,267
USG Staff Salaries and Benefits - Locally Recruited		240,374		240,374	0	240,374
<b>Total</b>	<b>512,500</b>	<b>2,585,859</b>	<b>0</b>	<b>3,098,359</b>	<b>0</b>	<b>3,098,359</b>



**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		4,000		4,000	0	4,000
ICASS		58,484		58,484	0	58,484
Management Meetings/Professional Development		25,000		25,000	0	25,000
Non-ICASS Administrative Costs		127,800		127,800	0	127,800
Staff Program Travel		30,000		30,000	0	30,000
USG Staff Salaries and Benefits - Locally Recruited		94,167		94,167	0	94,167
<b>Total</b>	<b>0</b>	<b>339,451</b>	<b>0</b>	<b>339,451</b>	<b>0</b>	<b>339,451</b>

**U.S. Peace Corps**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
-------------------------------	-----	-----------	-----------	----------------------	------------------	---

Approved



Non-ICASS Administrative Costs		62,349		62,349	0	62,349
Peace Corps Volunteer Costs		469,670		469,670	0	469,670
Staff Program Travel		23,346		23,346	0	23,346
USG Staff Salaries and Benefits - Locally Recruited		66,285		66,285	0	66,285
<b>Total</b>	<b>0</b>	<b>621,650</b>	<b>0</b>	<b>621,650</b>	<b>0</b>	<b>621,650</b>